The metrics — click any for its citations + threads

Posture med

mixed — expanding distribution (specialty-care/health-plan partnerships, new AI clinical model) while contracting cost base (workforce cuts, therapist-network downsizing); revenue trend … 4 src →

Capital · available med

~$0.5-0.6B cumulative raised across the pre-merger entities plus post-merger debt: Headspace pre-merger ~$216M total (incl. $93M Series C, Feb-2020) + Ginger pre-merger ~$213-220M total … 4 src →

Capital · operating low

Revenue estimates conflict sharply and should be treated as directional, not audited: GetLatka's third-party estimate puts 2025 ARR at ~$140M, DOWN from ~$348.4M in 2024 — an unusually large … 1 src →

Capital · deployed med

No disclosed capex/build figure; deployment is inferred from the cadence of specialty-care and channel launches in the last ~12 months rather than a stated $ amount (see thrust block below). 1 src →

Capital · in med

2021 merger equity round (Blackstone Growth + Bain Capital among backers, per Wikipedia/press) valuing the combined entity at $3B; $105M debt financing Jul-2023. No new equity round found … 2 src →

Capital · out med

No disclosed multi-year $ commitment for the 2025-2026 specialty-care/health-plan expansion wave (Navy, Ebb AI model, D2C insurance-backed therapy, Cigna, Care.com) — every source found is a … 1 src →

Optionality med

constrained — VC/PE-backed private company (Blackstone Growth, Bain Capital among post-merger backers, plus the pre-merger investor bases of both Headspace and Ginger); no evidence found of … 2 src →

Gravity low

~$0.2-0.35B/yr, estimated — grounded in revenue/contract scale (per the recipe, not gross download/subscriber headlines): third-party ARR estimates put Headspace at ~$140M (2025) to ~$348M … 3 src →